Fatal hepatic necrosis following imatinib mesylate therapy [1]

Blood

Volumn 102, Issue 9, 2003, Pages 3455-3456

  Lin, Nancy U ^b   Sarantopoulos, Stefanie ^b   Stone, James R ^b   Galinsky, Ilene ^b   Stone, Richard M ^b   Deangelo, Daniel J ^b   Soiffer, Robert J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; IMATINIB; PARACETAMOL; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; WARFARIN;

ADULT; BONE PAIN; CASE REPORT; DEEP VEIN THROMBOSIS; FEMALE; HEPATOSPLENOMEGALY; HISTOLOGY; HUMAN; HUMAN TISSUE; LETTER; LIVER FAILURE; LIVER NECROSIS; LUNG EMBOLISM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SEIZURE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0142214621     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2323     Document Type: Letter

References (12)

1. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-942.
2. Hoelzer D, Gokbuget N, Ottman OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol. 2002;39(suppl 3):32-37.
3. Dager R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034-3038.
4. Silver RT. Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003;17:1186-1187.
5. O'Brien SG, Guilhot F, Larson R, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
6. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
7. McBrine PA, Miller A, Zimelman AP, Koff RS. Polycythemia vera with myelofibrosis and myeloid metaplasia: acute hepatic failure following splenectomy. Am J Clin Pathol. 1980;74:693-696.
8. Holcombe RF, Treseler PA, Rosenthal DS. Chronic myelomonocytic leukemia transformation in polycythemia vera. Leukemia. 1991;5:606-610.
9. Shrestha R, Durham JD, Wachs M, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome. Am J Gastroenterol. 1997;92:2304-2306.
10. Cameron JL, Herlong HF, Sanfey H, et al. The Budd-Chiari syndrome: treatment by mesenteric-systemic venous shunts. Ann Surg. 1983;198:335-346.
11. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160-2161.
12. Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr. 1989;67:818-825.